1 Department of Dermatology and Skin Science, University of British Columbia and Probity Medical Research, Surrey, Canada.
2 Queen's University, SKiN Centre for Dermatology and Probity Medical Research, Peterborough, ON, Canada.
J Cutan Med Surg. 2019 Sep/Oct;23(4_suppl):5S-10S. doi: 10.1177/1203475419857669.
Topical calcineurin inhibitors (TCIs) were approved in the early 2000s for the treatment of atopic dermatitis (AD), and despite the recent introduction of newer topical and systemic therapies for AD, TCIs such as tacrolimus ointment (0.03% and 0.1%) and pimecrolimus cream (1%), remain recommended treatment options in contemporary management guidelines. The goal of this article is to review the evidence supporting the approved indications for TCIs in adults with AD, including short-term treatment of active disease and as intermittent or maintenance treatment for the prevention of flares. Other evidence reviewed in this article includes the treatment of specific body areas (such as the face and eyelids), combination or sequential use of TCIs with topical corticosteroids, and the comparative efficacy of the 2 commercially available TCIs. This review of the evidence confirms that TCIs remain an effective treatment option for the management of adult AD.
局部钙调磷酸酶抑制剂（TCIs）于 21 世纪初被批准用于治疗特应性皮炎（AD），尽管最近有新的局部和全身治疗 AD 的药物问世，但 TCI 如他克莫司软膏（0.03%和 0.1%）和吡美莫司乳膏（1%）仍被当代治疗指南推荐为治疗选择。本文的目的是回顾支持 TCI 治疗成人 AD 的适应证的证据，包括短期治疗活跃期疾病以及间歇性或维持治疗预防病情发作。本文还回顾了其他证据，包括治疗特定身体部位（如面部和眼睑）、TCI 与局部皮质类固醇联合或序贯使用，以及两种市售 TCI 的比较疗效。对证据的回顾证实，TCI 仍然是成人 AD 管理的有效治疗选择。
Zotero 插件